OMC
ABUS icon

Oasis Management Company’s Arbutus Biopharma ABUS Stock Holding History

Oasis Management Company’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,088,895
Closed -$2.54M – 78
2022
Q4 		$2.54M Buy
1,088,895
+62,223
+6% +$149K 0.5% 31
2022
Q3 		$1.96M Buy
+1,026,672
New +$2.42M 0.33% 39

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oasis Management Company's ABUS Position: Q1 2023 in Review

Oasis Management Company sold out of Arbutus Biopharma (ABUS) in Q1 2023, closing a stake of 1,088,895 shares — an estimated $2.54M sold.

Oasis Management Company first reported a position in ABUS in Q3 2022 and held it in 2 quarters. The position peaked at $2.54M in Q4 2022. 122 funds tracked by Wall St. Rank hold ABUS as of Q1 2023.

  • Oasis Management Company reported no remaining Arbutus Biopharma position as of Q1 2023 after selling out during the quarter.
  • Oasis Management Company sold 1,088,895 Arbutus Biopharma shares in Q1 2023, an estimated $2.54M.
  • Oasis Management Company first reported a position in Arbutus Biopharma in Q3 2022 and held it in 2 quarters.
  • Oasis Management Company's Arbutus Biopharma position peaked at $2.54M in Q4 2022.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2023.

Based on Oasis Management Company's 13F filing for Q1 2023, filed 15 May 2023.